BARBARA RODERICK: Open Payments
NPI 1295084002 · NEW BEDFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$706 in 23 payments from 10 companies in 2025. Trend: 2023 $358 · 2024 $218 · 2025 $706
Food & beverage: $706
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 3 | $171 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Alkermes, Inc. | 5 | $106 |
| ABBVIE INC. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: Qelbree, COBENFY, ARISTADA, VRAYLAR, CAPLYTA, REXULTI, Auvelity, INGREZZA.
Industry payments across MA — which companies pay providers there.
